Alex Mueller

Title: Alex Mueller: Inventor in Retinal Disease Research.

Introduction

Alex Mueller is an inventor based in Zurich, Switzerland, associated with Endogena Therapeutics, Inc. His patent work focuses on compounds and therapeutic approaches for retinal diseases and conditions involving the retinal pigment epithelium. His portfolio includes 6 patents.

Latest Patents

Mueller’s listed patent work includes “Compounds and Their Use as Therapeutically Active Substances in the Treatment and/or Prevention of Diseases Involving the Retinal Pigment Epithelium.” The invention describes methods of treating or preventing diseases involving the retinal pigment epithelium by administering specified compounds or their pharmaceutically acceptable forms.

Another listed patent is “N-(4-(Oxazol-5-yl)phenyl) Chromane-3-carboxamide Derivatives and Related Compounds as Stimulators of the Production of Retinal Precursor Cells for the Treatment of Neuroretinal Diseases.” It describes compounds and methods intended to address retinal diseases associated with photoreceptor loss or outer-retina degeneration.

Career Highlights

Mueller’s patent activity reflects a focus on therapeutic innovation in ophthalmology, particularly approaches targeting retinal degeneration and the production of retinal precursor cells. His work is associated with Endogena Therapeutics, Inc., a company working in the biotechnology field.

Collaborations

Mueller’s listed coworkers include Matthias Steger and Mauro Marigo. Their names appear alongside his work in the context of retinal therapeutics and related patent activity.

Conclusion

Alex Mueller’s patent portfolio centers on potential treatments for retinal and neuroretinal diseases, highlighting his contributions to therapeutic research associated with Endogena Therapeutics, Inc.